Wegovy Injection

Wegovy (Semaglutide) is a single-action GLP-1 receptor agonist and is the pioneer in this class of weight loss medications. Mounjaro (Tirzepatide) is a newer medication that activates both GIP and GLP-1 receptors simultaneously. While clinical trials show Mounjaro produces a slightly higher average weight loss (up to 22.5% vs 15%), Wegovy has a longer history of real-world use and proven cardiovascular benefits. Both are highly effective treatments.

Most patients notice a reduction in appetite and food cravings within the first 1–2 weeks of starting Wegovy. Visible weight loss typically becomes apparent by weeks 4–8. The most significant weight loss phase occurs between months 3 and 9 as doses are titrated upward. Average weight loss in the STEP trials reached around 15%.

All new patients start on Wegovy 0.25mg once weekly for the first 4 weeks. The dose is then increased every 4 weeks through 0.5mg, 1.0mg, 1.7mg, and up to 2.4mg. Our clinical team will guide your titration based on your tolerability and response.

NICE has approved Semaglutide (Wegovy) for NHS use in England, but access through NHS pathways remains limited to specialist tier-3 obesity services, which have significant waiting lists. Most patients who want to start Wegovy now access it through a private prescription service like Prescriptly. NHS provision is expected to expand gradually over the coming years as the specialist services scale up.

Yes — and switching is straightforward. Tell us your current dose during the consultation questionnaire and our prescribers will continue you at your existing dose without restarting titration. We time your first delivery so there is no gap in your medication, and we will guide you through cancelling with your previous provider if needed.

Wegovy is injected once weekly using the Wegovy FlexTouch pen, a pre-filled auto-injector pen. Each pen contains four weekly doses, so you only need one pen per month. The needle is very small (4mm) and most patients describe the injection as virtually painless. It is self-administered under the skin of the abdomen, thigh, or upper arm. We include full instructions with every order, and our clinical team is available if you have any questions about technique.

Wegovy is not suitable if you are pregnant, breastfeeding, or planning a pregnancy. It is contraindicated for those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also be avoided if you have severe gastrointestinal disease (like severe gastroparesis), a history of pancreatitis, or severe kidney impairment. Our comprehensive medical questionnaire will screen for all of these contraindications to ensure your safety.

Yes. Wegovy is a highly effective tool that makes eating less feel natural, but it is not a standalone magic cure. It is clinically licensed to be used as an adjunct to a reduced-calorie diet and increased physical activity. Incorporating a balanced, high-protein diet and regular resistance training will not only maximize your weight loss but also help preserve lean muscle mass during your treatment.

If you miss a dose of Wegovy and it has been 4 days (96 hours) or less since your scheduled dose, administer it as soon as possible. If more than 4 days have passed, skip the missed dose and administer your next dose on your regularly scheduled day. Do not administer two doses within 3 days (72 hours) of each other. If you miss multiple consecutive doses, contact our clinical team before resuming, as you may need to restart at a lower dose to avoid gastrointestinal side effects.

Unused Wegovy pens must be stored in a refrigerator (between 2°C and 8°C). Do not freeze them. Once you begin using a pen, it can be stored either in the refrigerator or at room temperature (up to 30°C) for up to 30 days. Keep the pen in its original carton to protect it from light, and never store a pen with a needle attached. We ship all Wegovy orders using specialised cold-chain packaging to ensure it arrives at the correct temperature.

Yes, obesity is increasingly recognized as a chronic metabolic condition, and Wegovy is designed and licensed for long-term weight management. Clinical trials have demonstrated its safety profile over extended periods. Stopping the medication usually results in a return of appetite and potential weight regain, which is why many patients opt to stay on a lower maintenance dose long-term. Our clinical team will work with you to establish the safest and most effective long-term plan for your biology.